Qiagen believes it has gained access to a relatively simple and inexpensive technology to bolster its offerings in the growing single-cell molecular biology market.
The firm reported revenues of $26.7 million, up 4 percent from $25.7 million in the year-ago period, but short of the Wall Street estimate of $30.7 million.
Speakers at the Association of Biomolecular Resource Facilities annual meeting discussed their approaches for single-cell genomic studies of tumor and immune cells.
At AGBT, Fluidigm showcased the Polaris system for integrated single-cell analysis and new applications for the C1, including high-throughput RNA-seq and protein analysis.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
